Works by Weimin Xie


Results: 39
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16

    ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer.

    Published in:
    Signal Transduction & Targeted Therapy, 2025, v. 10, n. 1, p. 1, doi. 10.1038/s41392-025-02149-3
    By:
    • Hu, Xichun;
    • Zhang, Qingyuan;
    • Wang, Leiping;
    • Zhang, Jian;
    • Ouyang, Quchang;
    • Wang, Xiaojia;
    • Li, Wei;
    • Xie, Weimin;
    • Tong, Zhongsheng;
    • Wang, Shusen;
    • Xu, Faliang;
    • Sun, Tao;
    • Liu, Wei;
    • Chen, Zhendong;
    • Wu, Jinsheng;
    • Wang, Ying;
    • Wang, Haixia;
    • Yan, Min;
    • Wang, Xinshuai;
    • Wang, Jingfen
    Publication type:
    Article
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39